Limiting Pharma Access to Physician Prescribing Data
Pharmaceutical companies use physician prescribing data for a variety of purposes, but arguably mostly for sales and marketing purposes.
Some doctors object to the use of prescribing data to target them for marketing. New Hamspire has recently passed a bill limiting the sales of physician Rx data to pharmaceutical companies for "commercial purposes," including -- but not limited to -- marketing purposes.
This surevy solicits your opinion on the benefits of pharma access to prescribing information, physicians ability to opt-out, and appropriate uses of Rx data by pharmaceutical companies.
Specifically, the survey asks whether you agree or disagree with each of the following statements:
- Prescribing data allow pharmaceutical promotion to be relevant and specific, making the whole process more cost-effective
- Physician prescribing data helps manufacturers to alert physicians of important new information about medicines in a timely fashion
- Physicians should be able to opt-out of having their Rx data sold to pharma companies for ANY USE
- Physicians should be able to opt-out of having their Rx data sold to pharma companies for MARKETING PURPOSES ONLY
- Physicians should NOT be able to opt-out of having their Rx data sold to pharma companies
- After completing the survey you will be able to see a summary of results (de-identified, excludes open-ended responses and comments that may identify the respondent). You can also use filters to examine results from different subsets of respondents (e.g., pharma company employees vs. non-pharma people, etc.).